173 related articles for article (PubMed ID: 3183418)
1. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G
J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
3. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis.
Levy MY; Polacheck I; Barenholz Y; Benita S
J Med Vet Mycol; 1993; 31(3):207-18. PubMed ID: 8360812
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
Souza LC; Campa A
J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
[TBL] [Abstract][Full Text] [Related]
5. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis.
Miyazaki T; Kohno S; Kaku M; Koga H; Yamaguchi K
Tohoku J Exp Med; 1990 Aug; 161(4):273-81. PubMed ID: 2256101
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.
Egito ES; Araújo IB; Damasceno BP; Price JC
J Pharm Sci; 2002 Nov; 91(11):2354-66. PubMed ID: 12379920
[TBL] [Abstract][Full Text] [Related]
8. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes).
Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T
Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers.
Lamb KA; Washington C; Davis SS; Denyer SP
J Pharm Pharmacol; 1991 Jul; 43(7):522-4. PubMed ID: 1682471
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.
Lopez-Berestein G; Mehta R; Hopfer RL; Mills K; Kasi L; Mehta K; Fainstein V; Luna M; Hersh EM; Juliano R
J Infect Dis; 1983 May; 147(5):939-45. PubMed ID: 6842027
[TBL] [Abstract][Full Text] [Related]
11. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of amphotericin B(Fungizone) in rat brain total lipid liposomes markedly decreases its i.v. toxicity in mice.
Gergel D; Ondrias K
Pharmazie; 1993 Mar; 48(3):202-5. PubMed ID: 8388108
[TBL] [Abstract][Full Text] [Related]
13. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
Brajtburg J; Elberg S; Travis SJ; Kobayashi GS
Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion.
Souza LC; Maranhão RC; Schreier S; Campa A
J Antimicrob Chemother; 1993 Jul; 32(1):123-32. PubMed ID: 8226403
[TBL] [Abstract][Full Text] [Related]
15. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis.
Lopez-Berestein G; Mehta R; Hopfer R; Mehta K; Hersh EM; Juliano R
Cancer Drug Deliv; 1983; 1(1):37-42. PubMed ID: 6544116
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex therapy of experimental fungal infections in mice.
Clark JM; Whitney RR; Olsen SJ; George RJ; Swerdel MR; Kunselman L; Bonner DP
Antimicrob Agents Chemother; 1991 Apr; 35(4):615-21. PubMed ID: 2069367
[TBL] [Abstract][Full Text] [Related]
17. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).
Adler-Moore JP; Chiang SM; Satorius A; Guerra D; McAndrews B; McManus EJ; Proffitt RT
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():63-71. PubMed ID: 1778893
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of experimental murine candidiasis with liposome-encapsulated amphotericin B].
Sasahara T
Kansenshogaku Zasshi; 1989 Dec; 63(12):1301-7. PubMed ID: 2621383
[TBL] [Abstract][Full Text] [Related]
19. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice.
Shadkchan Y; Segal E
J Antimicrob Chemother; 1999 Dec; 44(6):787-90. PubMed ID: 10590279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
